



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/821,734	03/30/2001	Artur Pedyczak	API-02-07-US	5460

7590  
Patrick J. Halloran  
Aventis Pasteur  
Discovery Drive  
Swiftwater, PA 18370

01/05/2004

EXAMINER
----------

HUFF, SHEELA JITENDRA

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 01/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application N .</b>		<b>Applicant(s)</b>	
	09/821,734		PEDYCZAK ET AL.	
	<b>Examin r</b>		<b>Art Unit</b>	
	Sheela J Huff		1642	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 14 November 2003.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 5-9 and 23-34 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 5,6,8,9 and 23-34 is/are rejected.
- 7) ☒ Claim(s) 7 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. §§ 119 and 120**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All   b) ☐ Some \*   c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.  
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                             | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                    | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other:  |

## **DETAILED ACTION**

### ***Response to Amendment***

The amendment filed on 11/14/03 has been considered. Applicant's arguments are deemed to be persuasive. All rejections are withdrawn in view of applicant's amendment.

Additionally, the election of species between SEQ ID No. 12-17 is hereby withdrawn and the sequences have been examined.

Claims 5-9 and 23-34 are pending.

### ***Information Disclosure Statement***

The documents submitted 11/14/093 have been considered and an initialed copy of the PTO1449 is enclosed. The only two references not found were #22 and #41. Applicant indicates that these will be submitted shortly.

### ***Declaration***

The declaration remains defective for the reasons of record. Applicant indicates that a new declaration will be filed shortly.

### ***New Grounds of Rejection***

***Claim Rejections - 35 USC § 112***

Claims 26-28 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The terminology "shorter than" is new matter. On page 8 the specification states that the sequence cannot be less than 5 amino acids in length. The instant claims read on peptides of 2-4 amino acids in length.

Claims 5-6, 8-9 and 23-34 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a nucleic acid sequence encoding SEQ ID NO. 12-17, does not reasonably provide enablement for a nucleic acid sequence encoding X-X1-X-X-X-X-X-X2 or analogs or sequences with substantial sequence homology thereto. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Applicant claims a nucleic acid sequence encoding X-X1-X-X-X-X-X-X2 or analogs or sequences with substantial sequence homology thereto. In support of the claims, applicant provides SEQ ID No. 12-17. The amino acid sequences encoded by these nucleic acids are used to generate an immune response.

Changing the amino acid sequence of a peptide and retaining function is highly unpredictable. Protein chemistry is probably one of the most unpredictable areas of

Art Unit: 1642

biotechnology. For example, the replacement of a single lysine at position 118 of the acidic fibroblast growth factor by a glutamic acid led to a substantial loss of heparin binding, receptor binding, and biological activity of the protein (see Burgess et al, Journal of Cell Biology Vol 111 November 1990 2129-2138). In transforming growth factor alpha, replacement of aspartic acid at position 47 with asparagine, did not affect biological activity while the replacement with serine or glutamic acid sharply reduced the biological activity of the mitogen (see Lazar et al Molecular and Cellular Biology Mar 1988 Vol 8 No 3 1247-1252).

a. Replacement of the histidine at position 10 of the B-chain of human insulin with aspartic acid converts the molecule into a superagonist with 5 times the activity of nature human insulin. Schwartz et al, Proc Natl Acad Sci USA Vol 84:6408-6411 (1987). Removal of the amino terminal histidine of glucagon substantially decreases the ability of the molecule to bind to its receptor and activate adenylate cyclase. Lin et al Biochemistry USA Vol 14:1559-1563 (1975).

b. Although biotechnology has made great strides in the recent past, these references serve to demonstrate exactly how little we really know about the art. Elucidation off the genetic code induces one to believe that one can readily obtain a functional synthetic protein for any known nucleic acid sequence with predictable results. The results of the construction of synthetic proteins remain very unpredictable as Burgess et al, Lazar et al, Schwartz et al and Lin et al conclusively demonstrate.

Thus, since the amino acid sequence of a polypeptide determines its structural and functional properties, predictability of which changes can be tolerated in a polypeptide's amino acid sequence and still retain similar functionality (e.g. ligand or receptor) requires a knowledge of and guidance with regard to which amino acids in the polypeptide's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which a polypeptide's structure relates to its functional usefulness. However, the problem of predicting polypeptide structure from mere sequence data of a single amino acid sequence and in turn utilizing predicted structural determinations to ascertain binding or functional aspects ligands and receptors and finally what changes can be tolerated with respect thereto is complex and well outside the realm of routine experimentation. In re

Art Unit: 1642

Fisher, 166 USPQ 18 indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute.

Specifically with respect to the use of peptides consisting of X-X1-X-X-X-X-X-X-X2 or analogs or sequences with substantial sequence homology thereto and using these sequences to generate an immune response, Li et al (PNAS 77: 3211-3214, 1980) disclose that dissociation of immunoreactivity from other biological activities when constructing analogs (see entire document). Specifically on page 3211 (first column, first paragraph), the reference states "omission of a single amino acid residue at position 14 or 20 abolishes immunoreactivity yet gives retention of opiate potency". Furthermore, Lederman et al. (Molecular Immunology 28: 1171-1181, 1991) disclose that a single amino acid substitution in a common allele ablates binding of a monoclonal antibody (see entire document). Thus, these documents show that changing even one amino acid disrupts the ability of the antibody to bind to its target.

Thus in view of the unpredictability in the art with respect peptides and the ability of altered peptides to bind to antibody and in view of the lack of guidance, lack of examples and objective evidence to show otherwise, one skilled in the art would be forced into undue experimentation in order to practice the claimed invention.

### ***Allowable Subject Matter***

Claim 7 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

### ***Conclusion***


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 703-305-7866. The examiner can normally be reached on Tuesday 5:30am-11:30am and Fridays 6:00am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Application/Control Number: 09/821,734  
Art Unit: 1642

Page 6

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

  
Sheela J Huff  
Primary Examiner  
Art Unit 1642

sjh